KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$3.4 million.

  • Emergent BioSolutions' Cash from Investing Activities fell 103.04% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.9 million, marking a year-over-year increase of 19.60%. This contributed to the annual value of $125.2 million for FY2024, which is 41.03% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Cash from Investing Activities is -$3.4 million, which was down 119.77% from $17.2 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Cash from Investing Activities ranged from a high of $257.7 million in Q2 2023 and a low of -$271.6 million during Q3 2022.
  • In the last 3 years, Emergent BioSolutions' Cash from Investing Activities had a median value of -$3.4 million in 2025 and averaged $37.3 million.
  • In the last 5 years, Emergent BioSolutions' Cash from Investing Activities plummeted by 392.03% in 2022 and then spiked by 902.80% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cash from Investing Activities (Quarterly) stood at -$45.8 million in 2021, then climbed by 0.87% to -$45.4 million in 2022, then surged by 74.89% to -$11.4 million in 2023, then skyrocketed by 350.88% to $28.6 million in 2024, then crashed by 103.04% to -$3.4 million in 2025.
  • Its Cash from Investing Activities was -$3.4 million in Q3 2025, compared to $17.2 million in Q2 2025 and $59.5 million in Q1 2025.